Product Description
a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18983233/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | China | Colombia | Croatia | Dominican Republic | Egypt | Estonia | Germany | Hong Kong | Hungary | India | Italy | Japan | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Unknown Location
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Oncology Unspecified|Other
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2018-000663-80 | P3 |
Active, not recruiting |
Oncology Unspecified |
2019-05-11 |
|
| CTR20191829 | P1 |
Active, not recruiting |
Healthy Volunteers |
None |
|
| CTR20200963 | P3 |
Recruiting |
Other |
None |
|
| CTR20222107 | P3 |
Not yet recruiting |
Other |
None |